# US 2010/0074843 A1 · Novel Substrate Based PET Imaging Agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0074843 A1
- Document ID: US20100074843A1
- Status: Published application
- Kind: A1
- Application number: 12/433,211
- Filed: 2009-04-30
- Published: 2010-03-25
- Earliest claimed: 2008-04-30
- Assignees: Siemens Medical Solutions USA, Inc.
- Inventors: Hartmuth C. Kolb; Joseph C. Walsh; Kai Chen; Umesh B. Gangadharmath; Gang Chen; Vani P. Mocharla; Dhanalakshmi Kasi; Peter J.H. Scott; Qianwa Liang
- Web page: https://patentgrep.com/patent/US20100074843A1

## CPC

- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- G01N 33/60: involving radioactive labelled substances
- G01N 2333/96466: Cysteine endopeptidases (3.4.22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present application is directed to radiolabeled imaging agents comprising a radiolabel, and a substrate, pharmaceutical compositions comprising radiolabeled imaging agents, and methods of using the radiolabeled imaging agents. The present application is further directed to methods of preparing the radiolabeled imaging agent. Such imaging agents can used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).

## Claims

### Claim 1

An imaging agent comprising a compound of formula I:
wherein:
X is a bond or a linker connected to an N-terminus of a peptide substrate;
Y is a bond or a linker;
RL is a radiolabel;
Sub is a peptide substrate;
CPV is a cell permeating vector;
Z is a capping group;
m, n, p, and s are independently 0-4;
t is 0 or 1; and
u is 1 or 2;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The imaging agent of claim 1 wherein,
X is a bond or a linker connected to an N-terminus of a peptide substrate;
Y is a bond or a linker;
RL is a radiolabel,
Sub is a peptide substrate;
CPV is a cell permeating vector;
Z is a capping group;
m, p, and s are independently 0-4;
n is 0;
t is 1; and
u is 1.

### Claim 3 (depends on 1)

The imaging agent of claim 1 wherein,
Xm is a bond or X2X3X4, wherein X2 is a (C1-10)alkylenyl group, aryl group or heteroaryl group, X3 is a heteroaryl group or —C═N—O—, X4 is a (C1-10)alkylenyl group, wherein one of the (C1-10)alkylenyl carbon atoms is optionally replaced with —CO—, —CONR″—, —NR″CO—, —NR″—, —O— or —S—;
Y is a bond or a linker;
RL is a radiolabel selected from the group consisting of 11C or 18F;
Sub is a peptide substrate selected from the group consisting of -DEVD-, -DE(N-alkyl V)D, -DEVDD, -DNLD-, -DQTD-, -DMQD-, -YVDA-, -YEVD-, -LEVD-, LEHD-, -DQMD-, VDQQD-, -VDVDA-, -VEID-, -VQVD-, -YVADGW-, -VDVAD-, -VDVADGW-, -RGVDQQDGKNHW-, -GVDQQDGKNW-, -VDQQDGKNW-, -DQQDGKNW-, -QQDGKNW-, -VDQQDGKW-, -VDQQDW-, -VDQQDW-, -WEHD-, -YVAD-, -AEVD-, -IETD-, -AEVD, -VEHD-, -XEXDAMC-, -DEVDAMC, -VEHDAMC-, -VADFMK-, -YEVDGW-, -LEVDGW-, -VDQMDGW-, -VDVADGW-, -VQVDGW-, -VDQVDGW-, -DEVDAMC-, -VD-fmk-, -VAD-fmk-, -YVAD-fmk-, -ID-fmk-, -LD-fmk, -FD-fmk-, -AD-fmk-, -GD-fmk-, -KD-fmk-, -ED-fmk- and -DEVDAFC-;
CPV is selected from the group consisting of polyethyleneimine, PEG, PEI-PEG, PEG-PEI, Lys4, polyamines, histidylated poly-L-lysine, polyarginine, polyornithine, cationic liposomes and lipids, saccharide derivatives and polylysine;
Z is a capping group;
p is 0-4;
n is 0;
s is 1;
t is 1; and
u is 1.

### Claim 4 (depends on 1)

The imaging agent of claim 1 wherein,
Xm is X2X3X4, wherein X2 is a (C2-6)alkylenyl group or aryl, X3 is a heteroaryl group or —C═N—O—, X4 is a (C1-10)alkylenyl group, wherein one of the (C1-10)alkylenyl carbon atoms is optionally replaced with —CO—;
Y is a bond or a linker;
RL is 18F;
Sub is a peptide substrate selected from the group consisting of -DEVD-, -DE(N-alkyl V)D-, -DEVDD-, -DNLD-, -DQTD-, -DMQD-, -YVDA-, -YEVD-, -LEVD-, -LEHD-, -DQMD-, VDQQD-, -VDVDA-, -VEID-, -VQVD-, -YVADGW- and -VDVAD;
CPV is selected from the group consisting of a polyethyleneimine, PEG, PEI-PEG, PEG-PEI, Lys4, polyamines, histidylated polyarginine, polyornithine, cationic liposomes and lipids, saccharide derivatives and polylysine;
Z is a capping group;
p is 0-4;
n is 0;
s is 1;
t is 1; and
u is 1.

### Claim 5 (depends on 1)

The imaging agent of claim 1 wherein,
Xm is X2X3X4, wherein X2 is —(CH2)2—, X3 is a triazole, X4 is —CH2C(O)—;
Y is a -AlaNH—;
RL is 18F;
Sub is -DEVD;
CPV is (—CH2CH2O—)4;
Z is —CH2CH2CO2H;
n is 0;
s is 1;
t is 1; and
u is 1.

### Claim 6 (depends on 1)

The imaging agent of claim 1 wherein,
X is a bond or a linker connected to an N-terminus of a peptide substrate;
Y is a bond or a linker;
RL is a radiolabel;
Sub is a peptide substrate;
CPV is a cell permeating vector;
Z is a capping group;
m, p, and n are independently 0-4;
s is 0;
t is 1; and
u is 1.

### Claim 7 (depends on 1)

The imaging agent of claim 1 wherein,
Xm is X2X3X4, wherein X2 is C1-C6alkylene, X3 is a heteroaryl group, X4 is a (C1-10)alkylenyl group, wherein one of the (C1-10)alkylenyl carbon atoms is optionally replaced with —CO—;
Y is a bond or a linker;
RL is 18F;
Sub is a peptide substrate selected from the group consisting of -DEVD-, -DE(N-alkyl V)D-, -DEVDD-, -DNLD-, -DQTD-, -DMQD-, -YVDA-, -YEVD-, -LEVD-, -LEHD-, -DQMD-, VDQQD, -VDVDA-, -VEID-, -VQVD-, -YVADGW- and -VDVAD;
CPV is selected from the group consisting o a polyethyleneimine, PEG, PEI-PEG, PEG-PEI, Lys4, polyamines, histidylated poly-L-lysine, polyarginine, polyornithine, cationic liposomes and lipids, saccharide derivatives and polylysine;
Z is a capping group;
p is 0-4;
n is 1;
s is 0;
t is 1; and
u is 1.

### Claim 8 (depends on 1)

The imaging agent of claim 1 wherein the compound of formula (I) is

### Claim 9 (depends on 1)

The imaging agent of claim 1 wherein,
Xm is X2X3X4, wherein X2 is C1-C6alkylene, X3 is a heteroaryl group, X4 is a (C1-10)alkylenyl group, wherein one of the (C1-10)alkylenyl carbon atoms is optionally replaced with —CO—;
Y is a bond or a linker;
RL is 18F;
Sub is a peptide substrate selected from the group consisting of -DEVD-, -DE(N-alkyl V)D-, -DEVDD-, -DNLD-, -DQTD-, -DMQD-, -YVDA-, -YEVD-, -LEVD-, -LEHD-, -DQMD-, VDQQD-, -VDVDA-, -VEID-, -VQVD, -YVADGW- and -VDVAD;
CPV is independently selected from the group consisting of a polyethyleneimine, PEG, PEI-PEG, PEG-PEI, Lys4, polyamines, histidylated poly-L-lysine, polyarginine, polyornithine, cationic liposomes and lipids, saccharide derivatives and polylysine;
Z is a capping group;
p is 0-4;
n is 1;
s is 1;
t is 1; and
u is 1.

### Claim 10 (depends on 1)

The imaging agent of claim 1 wherein the compound of formula (I) is

### Claim 11 (depends on 1)

The imaging agent of claim 1, wherein the radiolabel is selected from the group consisting of 11C, 13N, 15O, 18F, 61Cu, 62Cu, 64Cu, 67Cu, 68Ga, 124I, 125I, 131I, 99Tc, 75Br, 153Gd and 32P.

### Claim 12 (depends on 11)

The imaging agent of claim 11, wherein the radiolabel is selected from the group consisting of 11C and 18F.

### Claim 13 (depends on 1)

The imaging agent of claim 1, wherein the radiolabel is a PET or SPECT based isotope.

### Claim 14 (depends on 13)

The imaging agent of claim 13, wherein the PET or SPECT based isotope is selected from the group consisting of 18F, 64Cu and 99mTc.

### Claim 15 (depends on 1)

The imaging agent of claim 1, wherein the radiolabel is linked to the substrate using click chemistry, chelation chemistry, oxime formation, or amide-based conjugation chemistry.

### Claim 16 (depends on 1)

The imaging agent of claim 1, wherein the substrate comprises a peptide fragment.

### Claim 17 (depends on 16)

The imaging agent of claim 16, wherein the peptide fragment is selected from the group consisting of a dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide and nonapeptide.

### Claim 18 (depends on 17)

The imaging agent of claim 17, wherein the peptide fragment is selected from the group consisting of -DEVD-, -DE(N-alkyl V)D-, -DEVDD-, -DNLD-, -DQTD-, -DMQD-, -YVDA-, -YEVD-, -LEVD-, -LEHD-, -DQMD-, VDQQD-, -VDVDA-, -VEID-, -VQVD-, -YVADGW-, -VDVAD-, -VDVADGW-, -RGVDQQDGKNHW-, -GVDQQDGKNW-, -VDQQDGKNW-, -DQQDGKNW-, -QQDGKNW-, -VDQQDGKW-, -VDQQDGW-, -VDQQDW-, -WEHD-, -YVAD-, -AEVD-, -IETD-, -AEVD-, -WEHD-, -VEHD-, -XEXDAMC-, -DEVDAMC, -VEHDAMC-, -VADFMK-, -YEVDGW-, -LEVDGW-, -VDQMDGW-, -VDVADGW-, -VQVDGW-, VDQVDGW-, -DEVDAMC, -VD-fmk-, -VAD-fmk-, -YVAD-fmk-, -ID-fmk-, -L-D-fmk, -FD-fmk-, -AD-fmk-, -GD-fmk-, -KD-fmk-, -ED-fmk- and -DEVDAFC-.

### Claim 19 (depends on 1)

The imaging agent of claim 1 wherein the substrate comprises a nucleic acid or polynucleotide.

### Claim 20 (depends on 1)

The imaging agent of claim 1, wherein the cell-permeating vector is selected from the group consisting of a polyethyleneimine, PEG, PEI-PEG, PEG-PEI, (Lys)4-, TAT peptide fragment, or saccharide derivative.

### Claim 21 (depends on 1)

The imaging agent of claim 1, wherein the cell-permeating vector is an amphiphilic moiety.

### Claim 22 (depends on 21)

The imaging agent of claim 21, wherein the amphiphilic moiety is selected from the group consisting of polyethyleneimine, polyamines, histidylated poly-L-lysine, polyarginine, polyornithine, cationic liposomes and lipids, and polylysine.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A method for a imaging reporter in vivo, the method comprising contacting the imaging agent of any one of claims 1 to 22 to a cell and imaging the reporter in-vivo.

### Claim 24 (depends on 23)

The method of claim 23, wherein the reporter is a protease or nuclease.

### Claim 25 (depends on 24)

The method of claim 24, wherein the protease is Caspase 3.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A method for detecting or diagnosing a disease involving abnormal apoptosis in a mammal, the method comprising administering an imaging agent of any one of claims 1 to 22 to the mammal, and detecting the presence of retained radioactivity in the mammal.

### Claim 27 (depends on 26)

The method of claim 26, wherein the detecting step employs a nuclear imaging technique selected from the group consisting of positron emission tomography (PET) and single photon emission computed tomography (SPECT) for monitoring a distribution of the imaging agent within the body or within a portion thereof.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method of visualizing caspase activity in a body of a patient, the method comprising: (a) administering to the patient the imaging agent of any one of claims 1 to 19; and (b) employing a nuclear imaging technique selected from the group consisting of positron emission tomography (PET) and single photon emission computed tomography (SPECT) for visualizing a distribution of the imaging agent within the body or within a portion thereof.
